{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:49:09Z","timestamp":1782647349305,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jpba.2022.114591","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:38:46Z","timestamp":1641814726000},"page":"114591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Determination of clozapine and norclozapine in dried plasma spot and dried blood spot by liquid chromatography-tandem mass spectrometry"],"prefix":"10.1016","volume":"210","author":[{"given":"Eliana","family":"Carniel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Adams","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"de Andrade de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Kohlrausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Venzon","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.114591_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpba.2022.114591_bib2","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.jpba.2022.114591_bib3","first-page":"192","article-title":"Concentrations in plasma clozapine levels in schizophrenic ans schizzoafective patients. Revista de Psiquiatr\u00eda y Salud Mental","volume":"10","author":"Garc\u00eda","year":"2017","journal-title":"Barcelona"},{"key":"10.1016\/j.jpba.2022.114591_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpba.2022.114591_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical rewiew of adverse effects and management","volume":"15","author":"Iqbal","year":"2003","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jpba.2022.114591_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"De Leon","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpba.2022.114591_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2006.01.011","article-title":"Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia","volume":"83","author":"Xiang","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpba.2022.114591_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2022.114591_bib9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1592\/phco.2005.25.9.1242","article-title":"Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy","volume":"25","author":"Patel","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2022.114591_bib10","first-page":"883","article-title":"Therapeuthic drug monitoring and LC-MS\/MS","volume":"33","author":"Adaway","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2022.114591_bib11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.pharep.2016.06.016","article-title":"The usefulness os monitored therapy using Clozapine concentration in the blood serum for determining drug dose in Polish schizophrenic patients","volume":"68","author":"Piwowarska","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jpba.2022.114591_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: clozapine pathway, pharmacokinetics","volume":"28","author":"Thorn","year":"2018","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.jpba.2022.114591_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpba.2012.11.044","article-title":"The stability of amitriptyline N-oxide and clozapine N-oxide on treated and untreated dry blood spot cards","volume":"76","author":"Temesi","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.114591_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/bmc.1367","article-title":"Dried blood spot sampling in combination with LC-MS\/MS for quantitative analysis of small molecules","volume":"24","author":"LI","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2022.114591_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.4155\/bio.15.100","article-title":"Are capillary DBS applicable for therapeutic drug monitoring of common antipsychotics? A proof of concept","volume":"7","author":"Patteet","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2022.114591_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.clinbiochem.2016.05.004","article-title":"Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring","volume":"49","author":"Antunes","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2022.114591_bib17","first-page":"1","article-title":"Method validation guidance for industry","author":"Bioanalytical","year":"2018","journal-title":"Dep. Health Hum. Serv. Food Drug Adm."},{"key":"10.1016\/j.jpba.2022.114591_bib18","unstructured":"European Medicines Agency, Guideline on bioanalytical method validation, (2015)."},{"key":"10.1016\/j.jpba.2022.114591_bib19","doi-asserted-by":"crossref","unstructured":"M.V. Antunes, S. Raymundo, S.C. Wagner, V.S. Mattevi, N. Vieira, R. Leite, F. Reginato, M.Z. Capra, L. Fogliatto, R. Linden, DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application, Bioanalysis, 7 02015) 2105\u20132117. Doi: 10.4155 \/ bio.15.101.","DOI":"10.4155\/bio.15.101"},{"key":"10.1016\/j.jpba.2022.114591_bib20","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.chroma.2011.01.071","article-title":"Rapid assays of clozapine and its metabolites in dried blood spots by liquid chromatography and microextraction by packed sorbent procedure","volume":"1218","author":"Saracino","year":"2011","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2022.114591_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jchromb.2018.04.019","article-title":"Development of a hematocrit-insensitive device to collect accurate volumes of dried blood spots without specialized skills for measuring clozapine and its metabolites as model analytes","volume":"1087\/ 1088","author":"Nakahara","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2022.114591_bib22","first-page":"502","article-title":"The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry, Drug Test","volume":"7","author":"Patteet","year":"2014","journal-title":"Analysis"},{"key":"10.1016\/j.jpba.2022.114591_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00216-020-03143-0","article-title":"Development, validation, and application of a quantitative volumetric absorptive microsampling\u2013based method in finger prick blood by means of LC-HRMS\/MS applicable for adherence monitoring of antipsychotics","volume":"413","author":"Jacobs","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2022.114591_bib24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/08039488.2017.1334821","article-title":"Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland","volume":"71","author":"Ingimarsson","year":"2017","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.jpba.2022.114591_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2003.01821.x","article-title":"Comparability of whole-blood and plasma clozapine and norclozapine concentrations","volume":"56","author":"Flanagan","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2022.114591_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.forsciint.2013.02.010","article-title":"LC\u2013MS\/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2022.114591_bib27","article-title":"Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics","volume":"168","author":"Leon","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpba.2022.114591_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1590\/0101-60830000000069","article-title":"Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in S\u00e3o Paulo","volume":"42","author":"Silveira","year":"2015","journal-title":"Braz., Arch. Clin. Psychiatry"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522000127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522000127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:21:10Z","timestamp":1760001670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522000127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":28,"alternative-id":["S0731708522000127"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114591","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of clozapine and norclozapine in dried plasma spot and dried blood spot by liquid chromatography-tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114591"}}